Publications

Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline

Necrobiosis Lipoidica (NL)

January 1, 1993

Noz KC, Korstanje MJ, Vermeer BJ.

Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro

Necrobiosis Lipoidica (NL)

February 1, 1992

Sullivan GW, Carper HT, Mandell GL.

Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer

PCS6422

October 1, 1989

Chang AY, Most C, Pandya KJ.

Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients

PCS6422

March 1, 1989

Hansen R, Quebbeman E, Ausman R, Frick J, Ritch P, Schulte W, Haas C, Beatty P, Anderson T.

Pentoxifylline for necrobiosis lipoidica diabeticorum

Necrobiosis Lipoidica (NL)

August 1, 1987

Littler CM, Tschen EH.

A clinical and pathological investigation of 171 cases

Necrobiosis Lipoidica (NL)

March 1, 1966

Muller SA, Winkelmann RK.

A clinical and pathological investigation of 171 cases

Necrobiosis Lipoidica (NL)

March 1, 1966

Muller SA, Winkelmann RK.

Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ib/IIa study

PCS3117

Jun Gong, Vincent M. Chung, Joel Picus, Scott T. Tagawa, Sumati Gupta, Julie Poore, Christine Peterson, Ely Benaim, Sumanta K. Pal; City of Hope Comprehensive Cancer Center, Duarte, CA; City of Hope, Duarte, CA; 2Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; 3Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Rexahn Pharmaceuticals, Inc., Rockville, MD

Preliminary Results From an Ongoing Phase 2a Study of RX 3117, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer ( aUC

PCS3117

Jacob J. Adashek , Sumanta K. Pal , Vincent M. Chung , Scott T. Tagawa , Joel Picus , Hani M. Babiker , Sumati Gupta , Raymond Wadlow Julie Poore , Christine Peterson , and Ely Benaim ; City of Hope, Duarte, CA; 2 Weill Cornell Medical College, New York, NY; Washington University in St. Louis Scer Center, Tucson, AZ; University of Utah Huntsman Cancerts, Fairfax, VA; Rexahn Pharmaceuticals Inc., Rockville, MD

RX-3117, An Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer

PCS3117

M.C. Maia, S.K. Pal, S.T. Tagawa, V. Chung, J. Picus, S. Gupta, J. Poore, C. Peterson, E. Benaim; Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA, US, Genitourinary Oncology, Weill Cornell Medical College, New York, US, Internal Medicine, Washington University School of Medicine, St. Louis, US,Division of Hematology, Huntsman Cancer Institute, Salt Lake City, UT, US, Clinical Operations, Rexahn Pharmaceuticals, Inc, Rockville, MD, US, Oncology, Rexahn Pharmaceuticals, Rockville, MD, US